Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Clinical Oncology, Assiut University Hospital, Assiut, Egypt.
Department of Clinical Oncology, Assiut University Hospital, Assiut, Egypt.
J Hepatocell Carcinoma. 2015 Sep 18;2:131-42. doi: 10.2147/JHC.S81309. eCollection 2015.
Chronic liver diseases (CLDs) encompass a wide range of illnesses, including nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and viral hepatitis. Deterioration of liver capacity, with subsequent progression into cirrhosis and hepatocellular carcinoma (HCC), ultimately leads to a further decrease in the hepatic reserve. The Child-Turcotte-Pugh scoring system is the standard tool for assessing underlying liver reserve capacity in routine practice and in clinical trials of CLD and HCC. In this review, we highlight the clinical significance of insulin-like growth factor-I (IGF-I) and the growth hormone (GH) signaling pathway in HCC. IGF-I could be a marker for liver reserve capacity in CLDs and HCC in clinical practice. This approach could improve the risk assessment and stratifications of patients on the basis of their underlying liver reserve, either before active treatment in routine practice or before they are enrolled in clinical trials.
慢性肝脏疾病（CLD）包括多种疾病，包括非酒精性脂肪性肝病、非酒精性脂肪性肝炎和病毒性肝炎。随着肝功能的恶化，进而发展为肝硬化和肝细胞癌（HCC），最终导致肝储备进一步减少。Child-Turcotte-Pugh 评分系统是评估慢性肝病和 HCC 患者肝储备能力的常规临床实践和临床试验中的标准工具。在这篇综述中，我们强调了胰岛素样生长因子-I（IGF-I）和生长激素（GH）信号通路在 HCC 中的临床意义。IGF-I 可能是 CLD 和 HCC 患者肝储备能力的标志物。这种方法可以根据患者的基础肝储备情况，在常规实践中进行积极治疗之前或在参加临床试验之前，改善对患者的风险评估和分层。
